Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00552058 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 439
- Enrollment target
NCT00552058: Completed Phase 3 study, sponsored by UCB Pharma.
NCT00552058 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 439 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00552058, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 439 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate efficacy of certolizumab pegol in inducing clinical remission in patients with moderate to severe Crohn's disease as compared with placebo based on Crohn's Disease Activity Index (CDAI) score at Week 6.
Primary Outcome
The percentage of subjects in clinical remission at Week 6 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less). CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
Interventions
- OTHER Placebo
- BIOLOGICAL certolizumab pegol (CDP870, CZP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 439 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
What the finished NCT00552058 record still lists
NCT00552058 is an interventional study that assigns participants to a tested intervention. The registered 439 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00552058 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00552058 about?
NCT00552058 is a clinical study titled "Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease". The primary objective of the study is to evaluate efficacy of certolizumab pegol in inducing clinical remission in patients with moderate to severe Crohn's disease as compared with placebo based on Crohn's Disease Activity Index (CDAI) score at Week 6.
What is the current status of trial NCT00552058?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 439 participants. The study started on 2008-03. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00552058?
The interventions under investigation include: Placebo (OTHER), certolizumab pegol (CDP870, CZP) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00552058?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00552058's enrollment target sits among peer trials
439 872nd of 2000 higher than 1,127 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05421663 · 439 participants · Phase 1
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
- NCT06235151 · 439 participants · Phase 3
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
- NCT05117619 · 440 participants · NA
The HOME Program for Individuals With Traumatic Brain Injury and Family Members
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia